BR112016002401A8 - Métodos para reduzir as taxas de exacerbação de asma usando benralizumab - Google Patents
Métodos para reduzir as taxas de exacerbação de asma usando benralizumabInfo
- Publication number
- BR112016002401A8 BR112016002401A8 BR112016002401A BR112016002401A BR112016002401A8 BR 112016002401 A8 BR112016002401 A8 BR 112016002401A8 BR 112016002401 A BR112016002401 A BR 112016002401A BR 112016002401 A BR112016002401 A BR 112016002401A BR 112016002401 A8 BR112016002401 A8 BR 112016002401A8
- Authority
- BR
- Brazil
- Prior art keywords
- benralizumab
- methods
- reducing
- asthma
- asthma exacerbation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dermatology (AREA)
- Bathtubs, Showers, And Their Attachments (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361864944P | 2013-08-12 | 2013-08-12 | |
| PCT/US2014/050080 WO2015023504A1 (en) | 2013-08-12 | 2014-08-07 | Methods for reducing exacerbation rates of asthma using benralizumab |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016002401A2 BR112016002401A2 (pt) | 2017-09-12 |
| BR112016002401A8 true BR112016002401A8 (pt) | 2018-06-12 |
Family
ID=52448837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016002401A BR112016002401A8 (pt) | 2013-08-12 | 2014-08-07 | Métodos para reduzir as taxas de exacerbação de asma usando benralizumab |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9441037B2 (enExample) |
| EP (1) | EP3033101B1 (enExample) |
| JP (4) | JP6746495B2 (enExample) |
| KR (2) | KR20220057637A (enExample) |
| CN (2) | CN105451760A (enExample) |
| AU (2) | AU2014306956B2 (enExample) |
| BR (1) | BR112016002401A8 (enExample) |
| CA (1) | CA2918105C (enExample) |
| CY (1) | CY1122132T1 (enExample) |
| DK (1) | DK3033101T3 (enExample) |
| ES (1) | ES2716906T3 (enExample) |
| HK (1) | HK1221644A1 (enExample) |
| HR (1) | HRP20190405T1 (enExample) |
| HU (1) | HUE042607T2 (enExample) |
| LT (1) | LT3033101T (enExample) |
| ME (1) | ME03348B (enExample) |
| MX (1) | MX368508B (enExample) |
| PL (1) | PL3033101T3 (enExample) |
| PT (1) | PT3033101T (enExample) |
| RS (1) | RS58404B1 (enExample) |
| RU (1) | RU2676333C2 (enExample) |
| SG (2) | SG11201600481UA (enExample) |
| SI (1) | SI3033101T1 (enExample) |
| SM (1) | SMT201900163T1 (enExample) |
| TR (1) | TR201903312T4 (enExample) |
| WO (1) | WO2015023504A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX368474B (es) | 2013-08-12 | 2019-10-04 | Astrazeneca Ab | Uso de benralizumab para mejorar síntomas de asma. |
| KR102337599B1 (ko) * | 2013-08-12 | 2021-12-10 | 아스트라제네카 아베 | 벤랄리주맙을 이용하여 천식 환자에서 강제 호기량을 증가시키는 방법 |
| SG10201807318RA (en) * | 2013-10-15 | 2018-09-27 | Astrazeneca Ab | Methods for treating chronic obstructive pulmonary disease using benralizumab |
| EP3892288A1 (en) * | 2013-10-24 | 2021-10-13 | Astrazeneca AB | Stable, aqueous antibody formulations |
| AU2015204674B2 (en) | 2014-01-10 | 2020-09-03 | Anaptysbio, Inc. | Antibodies directed against interleukin-33 (IL-33) |
| US10699274B2 (en) | 2015-08-24 | 2020-06-30 | Samsung Electronics Co., Ltd. | Apparatus and method for secure electronic payment |
| US10846696B2 (en) | 2015-08-24 | 2020-11-24 | Samsung Electronics Co., Ltd. | Apparatus and method for trusted execution environment based secure payment transactions |
| JP2018538249A (ja) | 2015-11-04 | 2018-12-27 | アストラゼネカ アクチボラグ | 好酸球性疾患における好酸球標的化治療薬に対する臨床応答の予測変数としてのジペプチジルペプチダーゼ−４およびペリオスチン |
| PL3565823T3 (pl) | 2017-01-04 | 2024-10-28 | Worg Pharmaceuticals (Zhejiang) Co., Ltd. | Peptydy S-arestyn oraz ich zastosowanie terapeutyczne |
| RU2698048C2 (ru) * | 2017-10-03 | 2019-08-21 | Закрытое Акционерное Общество "Биокад" | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα |
| TW202021983A (zh) * | 2018-09-21 | 2020-06-16 | 美商安納普提斯生物公司 | 用於嗜伊紅性氣喘之抗il-33療法 |
| TW202214692A (zh) * | 2020-06-05 | 2022-04-16 | 瑞典商阿斯特捷利康公司 | 治療患有鼻瘜肉的患者的重度氣喘之方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6018032A (en) | 1995-09-11 | 2000-01-25 | Kyowa Hakko Kogyo Co., Ltd. | Antibody against human interleukin-5-receptor α chain |
| US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| CA2402477A1 (en) | 2000-02-15 | 2001-08-23 | Kyowa Hakko Kogyo Co., Ltd. | Eosinophil-specific apoptosis inducer |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20070148170A1 (en) | 2005-10-03 | 2007-06-28 | Desjarlais John R | Fc Variants With Optimized Fc Receptor Binding Properties |
| AU2004279740A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition specifically binding to IL-5 receptor |
| US20060014680A1 (en) | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
| DK3072525T3 (en) * | 2007-05-14 | 2018-04-30 | Astrazeneca Ab | PROCEDURES FOR REDUCING BASOFILE CELL LEVELS |
| RU2383345C1 (ru) * | 2008-08-07 | 2010-03-10 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") | Способ лечения больных бронхиальной астмой |
| CN102365017A (zh) * | 2009-11-18 | 2012-02-29 | 美迪诺亚公司 | 哮喘急性恶化的治疗及减少哮喘患者住院治疗的可能性 |
| KR101615474B1 (ko) * | 2010-12-16 | 2016-04-25 | 제넨테크, 인크. | Th2 억제에 관한 진단 및 치료 |
| US8961965B2 (en) * | 2011-05-18 | 2015-02-24 | Medimmune, Llc | Methods of diagnosing and treating pulmonary diseases or disorders |
| US20140328839A1 (en) | 2011-11-01 | 2014-11-06 | Medlmmune, Llc | Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma |
| KR102337599B1 (ko) * | 2013-08-12 | 2021-12-10 | 아스트라제네카 아베 | 벤랄리주맙을 이용하여 천식 환자에서 강제 호기량을 증가시키는 방법 |
| MX368474B (es) | 2013-08-12 | 2019-10-04 | Astrazeneca Ab | Uso de benralizumab para mejorar síntomas de asma. |
-
2014
- 2014-08-07 WO PCT/US2014/050080 patent/WO2015023504A1/en not_active Ceased
- 2014-08-07 PT PT14835826T patent/PT3033101T/pt unknown
- 2014-08-07 ME MEP-2019-75A patent/ME03348B/me unknown
- 2014-08-07 BR BR112016002401A patent/BR112016002401A8/pt not_active Application Discontinuation
- 2014-08-07 DK DK14835826.0T patent/DK3033101T3/en active
- 2014-08-07 SG SG11201600481UA patent/SG11201600481UA/en unknown
- 2014-08-07 HU HUE14835826A patent/HUE042607T2/hu unknown
- 2014-08-07 SI SI201431109T patent/SI3033101T1/sl unknown
- 2014-08-07 US US14/453,942 patent/US9441037B2/en active Active
- 2014-08-07 RS RS20190305A patent/RS58404B1/sr unknown
- 2014-08-07 TR TR2019/03312T patent/TR201903312T4/tr unknown
- 2014-08-07 SG SG10202005560UA patent/SG10202005560UA/en unknown
- 2014-08-07 SM SM20190163T patent/SMT201900163T1/it unknown
- 2014-08-07 HK HK16109784.3A patent/HK1221644A1/zh unknown
- 2014-08-07 KR KR1020227013308A patent/KR20220057637A/ko not_active Ceased
- 2014-08-07 PL PL14835826T patent/PL3033101T3/pl unknown
- 2014-08-07 HR HRP20190405TT patent/HRP20190405T1/hr unknown
- 2014-08-07 CN CN201480043448.XA patent/CN105451760A/zh active Pending
- 2014-08-07 CN CN202010449434.5A patent/CN111588848A/zh active Pending
- 2014-08-07 MX MX2016001383A patent/MX368508B/es active IP Right Grant
- 2014-08-07 EP EP14835826.0A patent/EP3033101B1/en active Active
- 2014-08-07 CA CA2918105A patent/CA2918105C/en active Active
- 2014-08-07 KR KR1020167006559A patent/KR102390714B1/ko active Active
- 2014-08-07 LT LTEP14835826.0T patent/LT3033101T/lt unknown
- 2014-08-07 RU RU2016108723A patent/RU2676333C2/ru active
- 2014-08-07 AU AU2014306956A patent/AU2014306956B2/en active Active
- 2014-08-07 ES ES14835826T patent/ES2716906T3/es active Active
- 2014-08-07 JP JP2016534614A patent/JP6746495B2/ja active Active
-
2016
- 2016-09-02 US US15/255,508 patent/US20170198049A1/en not_active Abandoned
-
2019
- 2019-03-12 CY CY20191100294T patent/CY1122132T1/el unknown
-
2020
- 2020-02-24 AU AU2020201327A patent/AU2020201327A1/en not_active Abandoned
- 2020-04-03 JP JP2020067797A patent/JP2020128375A/ja not_active Withdrawn
-
2022
- 2022-06-07 JP JP2022092216A patent/JP2022120009A/ja active Pending
-
2024
- 2024-07-05 JP JP2024108991A patent/JP2024129139A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016002401A8 (pt) | Métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
| AU2014284235B2 (en) | Methods for treating nasal polyposis by administering an IL-4R antagonist | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| BR112016016916A8 (pt) | uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae) | |
| MX2021013327A (es) | Anticuerpo anti-receptor cgrp para usarse en tratar o prevenir dolor de cabeza por migra?a. | |
| BR112014024494A2 (pt) | dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos | |
| BR112013021863A2 (pt) | anticorpos anti-receptor il-6 e métodos de uso | |
| CL2015000352A1 (es) | Métodos de tratamiento de una tauopatía | |
| AR090923A1 (es) | Anticuerpos anti-il-23 | |
| AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
| EP4406610A3 (en) | Treatment of cancer using anti-cd19 chimeric antigen receptor | |
| AR081750A1 (es) | Anticuerpos anti-cd40 | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| UY35718A (es) | Anticuerpos anti-csf-1r: métodos de expresión de los mismos. | |
| CR20130632A (es) | El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico | |
| PH12016500753A1 (en) | Antibodies specific to fcrn | |
| BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
| SA518391028B1 (ar) | Cd37 أجسام مضادة واختبارات للكشف عن | |
| BR112016010336A2 (pt) | Anticorpo anti-humano-her3 alostérico não competitivo com neuregulina, fragmento de anticorpo, sequência de ácido nucleico, vetor, célula hospedeira, composição farmacêutica e método para tratamento de câncer | |
| BR112019011461A2 (pt) | terapia celular à base de nk melhorada | |
| BR112017002729A2 (pt) | terapia de combinação para uso em um método para tratar um tumor sólido em um indivíduo, anticorpo, uso, composição farmacêutica, kit para tratar um tumor sólido, e, método para tratar um tumor sólido em um indivíduo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: ASTRAZENECA AB (SE) |
|
| B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: ASTRAZENECA AB (SE) |
|
| B25A | Requested transfer of rights approved |
Owner name: ASTRAZENECA AB (SE) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |